New cancer clinical trial: Trial of Olaparib in Patients With Metastatic Urothelial Cancer Harboring DNA Damage Response Gene Alterations

Published on: February 28, 2018 at 12:00PM
Condition:   Metastatic Urothelial Cancer
Intervention:   Drug: Olaparib
Sponsors:   Matthew Galsky;   Icahn School of Medicine at Mount Sinai;   AstraZeneca
Not yet recruiting
http://ift.tt/2F4F3Bo